Summary

This document aggregates vital regulatory and safety information regarding the Malaysian Drug Control Authority (DCA) and relevant bodies such as NPRA (National Product Registration Authority), DCA, and MADRAC. The text details the comprehensive regulatory framework governing all pharmaceutical and medical products in Malaysia, ensuring strict compliance with the Basic Regulation and various industry-specific documents like the DRGD. Consumers and healthcare professionals are protected through mechanisms for reporting side effects (AEFI), Quality Reports, and Vaccine Lot Releases, all managed by centralized systems like the QUEST license search. Key regulatory bodies include the NPRA, which requires 9001:2015 certifications, while DCA oversees quality control and complaints. The information also highlights specific updates for COVID-19, emphasizing Vaccine Lot Release Certificate notifications and Adverse Drug Reactions (ADR) reporting. Safety alerts are communicated directly via DHPCs, and the NCE section lists approved new chemical entities, biosimilars, and surface disinfectants. Furthermore, the document outlines how Product Recalls and Cancellations work for registered or unregistered products, reinforcing the DCA's goal of protecting consumers.

Title

National Pharmaceutical Regulatory Agency (NPRA) - Home

Description

National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Malaysia Drug Control Authority. Portal Rasmi Bahagian Regulatori Farmasi Negara.

Keywords

products, release, product, information, reporting, drug, safety, cosmetic, quality, health, compliance, quest, vaccines, cancellation, notification, slide, medicines

NS Lookup

A 103.42.207.44

Dates

Created 2026-04-15

Updated 2026-04-15

Summarized 2026-04-16